Aaron Edwards is the Co-Founder and CEO of KiraGen Bio, whose mission is to eliminate solid tumors with AI-driven, multiplex gene-edited CAR-T cells by advancing cell therapies that break through immunosuppressive tumor barriers—enabling effective and durable cancer control.
With a decade in cellular immunotherapy experience, Aaron has driven advancements in CAR-T and TCR-T therapies at bluebird bio, Beam Therapeutics, Eli Lilly, and more. Armed with a Harvard MS/MBA blending science and business, Aaron guides KiraGen Bio’s development of next-generation cell therapies, overseeing strategy, fundraising, and partnerships.
.png)
